Abstract:
AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment (using different frequencies of drug purchase) perspectives. METHODS:A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was developed. The model adopted a 5-year time horizon. Efficacy inputs were obtained from a mixed-treatment comparison analysis, and other model inputs were collected from published literature and local Japanese sources. Model outcomes included quality-adjusted life years (QALYs) and an incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained. The annual discounting rate of 2% was applied to both costs and outcomes. RESULTS:Results for the healthcare system perspective showed that secukinumab had the highest number of quality-adjusted life years (QALYs) (4.07) vs other biologics, dominated ustekinumab and infliximab, and the ICER of secukinumab compared to adalimumab was ¥8,418,222/QALY gained. In the patient co-payment perspective with the monthly purchase of drugs, ustekinumab had the lowest co-payment cost, followed by infliximab, adalimumab, and secukinumab. In the patient co-payment perspective with a once every 3 months purchase of secukinumab and adalimumab, the co-payment costs of secukinumab, adalimumab, and ustekinumab became comparable, and infliximab had the highest co-payment cost. LIMITATIONS:Only short-term efficacy data was modeled, as there was a lack of data on long-term outcomes. Treatment sequencing was restricted to first-line biologic treatment. Drop-out rates for comparators were assumed to be equivalent to secukinumab in the absence of available data. CONCLUSIONS:Secukinumab is a cost-efficient treatment for moderate-to-severe psoriasis, providing greater health outcomes to patients at lower total costs compared to infliximab and ustekinumab, as well as comparable patient co-payment relative to other biologic treatments.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Igarashi A,Igarashi A,Graham CN,Gilloteau I,Tani Ydoi
10.1080/13696998.2018.1532905subject
Has Abstractpub_date
2018-10-26 00:00:00pages
1-9eissn
1369-6998issn
1941-837Xpub_type
杂志文章abstract:AIMS:Improvements in information technology have granted the recent development of rapid, cloud-enabled, onsite laboratory testing for rheumatoid arthritis (RA). This study aims to quantify the value to payers of such technologies. MATERIALS AND METHODS:To calculate the value of rapid, cloud-enabled, onsite laboratory...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1502191
更新日期:2018-11-01 00:00:00
abstract:AIMS:Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the ap...
journal_title:Journal of medical economics
pub_type: 杂志文章,随机对照试验
doi:10.1080/13696998.2018.1515082
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable b...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1484372
更新日期:2018-09-01 00:00:00
abstract::Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chronic migraine using new utility estimates in an existing model structure.Methods: A previously published model was revised to...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1675417
更新日期:2020-01-01 00:00:00
abstract:AIMS:This paper evaluates the impact of multiple sclerosis (MS) in Ireland, and estimates the associated direct, indirect, and intangible costs to society based on a large nationally representative sample. MATERIALS AND METHODS:A questionnaire was developed to capture the demographics, disease characteristics, healthc...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1427100
更新日期:2018-05-01 00:00:00
abstract::Background: IVF is now a wide spread procedure globally, and currently 65 countries report annually all or part of their IVF/ICSI cycles, from which the International Committee Monitoring progress in Assisted Reproduction Technology (ICMART) published its report. There is considerable variation in the utilization (num...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1609484
更新日期:2019-09-01 00:00:00
abstract:OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.729549
更新日期:2013-01-01 00:00:00
abstract:BACKGROUND:Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a...
journal_title:Journal of medical economics
pub_type: 杂志文章,随机对照试验
doi:10.1080/13696998.2017.1331912
更新日期:2017-08-01 00:00:00
abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.991788
更新日期:2015-04-01 00:00:00
abstract:AIMS:Percutaneous closure of a patent foramen ovale (PFO) is known to lower the risk of recurrent stroke in patients with a cryptogenic stroke. However, the economic implications of transcatheter PFO closure are less well known. From a UK payer perspective, a detailed economic appraisal of PFO closure was performed for...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1548355
更新日期:2019-02-01 00:00:00
abstract:OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.624144
更新日期:2012-01-01 00:00:00
abstract::Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1627364
更新日期:2019-10-01 00:00:00
abstract::Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1613239
更新日期:2019-08-01 00:00:00
abstract:OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1093493
更新日期:2016-01-01 00:00:00
abstract::Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1688821
更新日期:2020-03-01 00:00:00
abstract:OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.675890
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVES:To assess the costs of severe hypoglycaemic events (SHEs) in diabetes patients in Germany, Spain and the UK. METHODS:Healthcare resource use was measured by surveying 639 patients aged ≥ 16 years, receiving insulin for type 1 (n=319) or type 2 diabetes (n=320), who experienced ≥ 1 SHE in the preceding year....
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696990903336597
更新日期:2009-01-01 00:00:00
abstract:AIMS:The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) and costs in patients with MDD treated with atypical antipsychotic (AAP) adjunctive therapy early or later in treatment. MATERIALS AND METHODS:Adults with MDD and antidepressant treatment (ADT) who newly initiat...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1484373
更新日期:2018-09-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.902844
更新日期:2014-05-01 00:00:00
abstract::Aims: Due to the lack of studies evaluating compliance or persistence with Alzheimer's Disease (AD) treatment outside High-Income Countries (HICs), this study aimed to assess compliance, persistence, and factors associated with non-compliance and non-persistence by utilizing existing "real-world" information from mult...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1534739
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known safety profiles with toxicities that may require hospitalizations. However...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.610394
更新日期:2011-01-01 00:00:00
abstract:INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1580200
更新日期:2019-05-01 00:00:00
abstract:OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1061533
更新日期:2015-01-01 00:00:00
abstract:INTRODUCTION:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.903257
更新日期:2014-06-01 00:00:00
abstract:INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1032974
更新日期:2015-01-01 00:00:00
abstract:OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2016.1187150
更新日期:2016-10-01 00:00:00
abstract:OBJECTIVE:The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases tha...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.622323
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Neuroblastoma (NB) is notorious in childhood cancer because of its high incidence and poor prognosis. The Children's Oncology Group reported that the 3-year OS in the high-risk (HR) group is 50%, and the HR-NB with bone marrow metastasis in our center is 43.1%. Thousands of families in China suffer from the ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1786392
更新日期:2020-09-01 00:00:00
abstract:AIM:Renal failure is a growing public health problem, and is mainly treated by hemodialysis. This study aims to estimate the societal costs of hemodialysis in Lebanon. METHODS:This was a quantitative, cross-sectional cost-of-illness study conducted alongside the Nutrition Education for Management of Osteodystrophy tri...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2016.1207653
更新日期:2016-12-01 00:00:00
abstract:OBJECTIVE:To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS:National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utiliz...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.885907
更新日期:2014-03-01 00:00:00